Ocular Therapeutix
OCUL
69 hedge funds and large institutions have $60.1M invested in Ocular Therapeutix in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 73 → 69 (-4)
7.74% less ownership
Funds ownership: 53.62% → 45.88% (-7.7%)
13% less call options, than puts
Call options by funds: $378K | Put options by funds: $434K
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
38% less capital invested
Capital invested by funds: $96.5M → $60.1M (-$36.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$409K |
| 2 |
VF
Virtu Financial
New York
|
+$322K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$214K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$196K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$153K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
-$6.63M |
| 2 |
JP Morgan Chase
New York
|
-$1.56M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.07M |
| 4 |
B
Bailard
Foster City,
California
|
-$907K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$599K |
OCUL Hedge Fund Activity: Q4 2017 in Review
69 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2017, worth a combined $60.1M — down 38% from $96.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of OCUL and 11 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 18 added.
The largest buyer was Hikari Power, opening a new position worth an estimated $409K. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $6.63M sold.
- 69 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2017, down from 73 in Q3 2017.
- Funds reported $60.1M of Ocular Therapeutix stock for Q4 2017, down 38% quarter-over-quarter.
- 11 funds opened new Ocular Therapeutix positions in Q4 2017 and 15 closed out, a net change of -4 holders.
- The largest Ocular Therapeutix buyer in Q4 2017 was Hikari Power, an estimated $409K added.
- The largest Ocular Therapeutix seller in Q4 2017 was Columbus Circle Investors, an estimated $6.63M sold.
Based on aggregated 13F filings for Q4 2017.